ARDS update: Are new therapies improving clinical outcomes? Efforts to target specific processes and potentially decrease mortality

P. G. Arndt, E. Abraham

Research output: Contribution to journalReview article

Abstract

In 30 years, ARDS has become a well-recognized clinical entity. Mortality has exceeded 50%, but some studies suggest a decline, possibly because of improved patient care. New therapies have been investigated in an effort to reduce mortality. These include newer ventilatory strategies, surfactant repletion, anti-inflammatory agents, and antioxidants. New ventilatory strategies are designed to prevent further lung damage by limiting tidal volume and airway pressures. Exogenous surfactant or fluorocarbons may improve oxygenation and lung compliance. Among the anti- inflammatory agents, corticosteroids may be most beneficial when used later in the course of ARDS, when parenchymal fibrosis is most likely to develop. Antioxidants may decrease lipid peroxidation and the resultant increases in vascular permeability and interstitial edema.

Original languageEnglish (US)
Pages (from-to)161-172
Number of pages12
JournalJournal of Critical Illness
Volume13
Issue number3
StatePublished - Dec 1 1998

Fingerprint

Surface-Active Agents
Anti-Inflammatory Agents
Antioxidants
Lung Compliance
Fluorocarbons
Mortality
Tidal Volume
Capillary Permeability
Lipid Peroxidation
Edema
Patient Care
Adrenal Cortex Hormones
Fibrosis
Pressure
Lung
Therapeutics

Cite this

ARDS update : Are new therapies improving clinical outcomes? Efforts to target specific processes and potentially decrease mortality. / Arndt, P. G.; Abraham, E.

In: Journal of Critical Illness, Vol. 13, No. 3, 01.12.1998, p. 161-172.

Research output: Contribution to journalReview article

@article{ffbbf3ad4db54e0599463700bcb17a84,
title = "ARDS update: Are new therapies improving clinical outcomes? Efforts to target specific processes and potentially decrease mortality",
abstract = "In 30 years, ARDS has become a well-recognized clinical entity. Mortality has exceeded 50{\%}, but some studies suggest a decline, possibly because of improved patient care. New therapies have been investigated in an effort to reduce mortality. These include newer ventilatory strategies, surfactant repletion, anti-inflammatory agents, and antioxidants. New ventilatory strategies are designed to prevent further lung damage by limiting tidal volume and airway pressures. Exogenous surfactant or fluorocarbons may improve oxygenation and lung compliance. Among the anti- inflammatory agents, corticosteroids may be most beneficial when used later in the course of ARDS, when parenchymal fibrosis is most likely to develop. Antioxidants may decrease lipid peroxidation and the resultant increases in vascular permeability and interstitial edema.",
author = "Arndt, {P. G.} and E. Abraham",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "13",
pages = "161--172",
journal = "Journal of Critical Illness",
issn = "1040-0257",
publisher = "Cliggott Publishing Co.",
number = "3",

}

TY - JOUR

T1 - ARDS update

T2 - Are new therapies improving clinical outcomes? Efforts to target specific processes and potentially decrease mortality

AU - Arndt, P. G.

AU - Abraham, E.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - In 30 years, ARDS has become a well-recognized clinical entity. Mortality has exceeded 50%, but some studies suggest a decline, possibly because of improved patient care. New therapies have been investigated in an effort to reduce mortality. These include newer ventilatory strategies, surfactant repletion, anti-inflammatory agents, and antioxidants. New ventilatory strategies are designed to prevent further lung damage by limiting tidal volume and airway pressures. Exogenous surfactant or fluorocarbons may improve oxygenation and lung compliance. Among the anti- inflammatory agents, corticosteroids may be most beneficial when used later in the course of ARDS, when parenchymal fibrosis is most likely to develop. Antioxidants may decrease lipid peroxidation and the resultant increases in vascular permeability and interstitial edema.

AB - In 30 years, ARDS has become a well-recognized clinical entity. Mortality has exceeded 50%, but some studies suggest a decline, possibly because of improved patient care. New therapies have been investigated in an effort to reduce mortality. These include newer ventilatory strategies, surfactant repletion, anti-inflammatory agents, and antioxidants. New ventilatory strategies are designed to prevent further lung damage by limiting tidal volume and airway pressures. Exogenous surfactant or fluorocarbons may improve oxygenation and lung compliance. Among the anti- inflammatory agents, corticosteroids may be most beneficial when used later in the course of ARDS, when parenchymal fibrosis is most likely to develop. Antioxidants may decrease lipid peroxidation and the resultant increases in vascular permeability and interstitial edema.

UR - http://www.scopus.com/inward/record.url?scp=0032469907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032469907&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0032469907

VL - 13

SP - 161

EP - 172

JO - Journal of Critical Illness

JF - Journal of Critical Illness

SN - 1040-0257

IS - 3

ER -